In a recent study of therapeutic APAP dosing looking at protein adduct formation, what was the major difference between females and males?
Arnold CG et al. performed a secondary analysis in subjects receiving 4 grams APAP daily for greater than or equal to 16 days and grouped subjects into adduct formation versus no adduct formation. Odds of males developing NAPQI protein adducts at therapeutic APAP dosing were 5.91 times lower than females. (95% CI = 2.3 -14.9; p = 0.0001).
Arnold CG et al. Metabolomic Evaluation of N-Acetyl-p-Benzoquinone Imine Protein Adduct Formation with Therapeutic Acetaminophen Administration:: Sex-based Physiologic Differences. JMT. Published online 24 June 2022. https://doi.org/10.1007/s13181-022-00903-5
Posted in Question Of The Day